If this message is not displayed correctly, click here.

 

ERA-EDTA FLASH is the official ERA-EDTA E-NEWSLETTER

No 139, May 2018

 

Editor in Chief: Mustafa Arici - Editorial Secretariat: Valentina Cocchi - Newsletter Design: Ilaria Martini
ERA-EDTA Headquarters - Via XXIV Maggio, 38 - 43123 Parma - Italy

 
Education
Research
Institutional
Association
 
 
Image
Image

Just presented in the Late Breaking Clinical Trials' Session

Michael Walsh, Hamilton, Canada: The effects of plasma exchange and reduced-dose glucocorticoids on severe ANCA associated vasculitis
In the multicentre, international, open-label, randomised controlled PEXIVA trial, treatment with reduced-dose glucocorticoids, compared to a standard dose, resulted in fewer serious infections and did not substantially increase the risk of death or end-stage renal disease in severe ANCA-associated vasculitis (AAV). However, plasma exchange did not lower the risk of end-stage renal disease or death in these patients.
David Jayne, Cambridge, United Kingdom: A phase III, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of abatacept or placebo on the standard of care in patients with active class III or IV lupus nephritis
In the randomised, multicentre, double-blind phase 3 ALLURE trial, the selective T-cell co-stimulation modulator abatacept was not superior to placebo on the primary study endpoint of complete response at one year in patients with active proliferative class III or IV lupus nephritis. However, compared with placebo, treatment with abatacept resulted in a more rapid improvement in proteinuria, which led to earlier and sustained complete remission.
Ron T. Gansevoort, Groningen, The Netherlands: Renoprotective efficacy and safety of the somatostatin analogue lanreotide in later stage ADPKD
In a randomised clinical trial in patients with late-stage autosomal dominant polycystic kidney disease (ADPKD), treatment with the somatostatin analog lanreotide did not improve the rate of eGFR loss. Although lanreotide significantly slowed kidney volume growth, it had no effect on the incidence of worsening kidney function, change in eGFR, or the change in quality of life.  Lanreotide was also associated with an increased incidence of adverse events. 
Geoffrey Block, Denver, U.S.A.: Randomised trial of ferric citrate in advanced chronic kidney disease
Ferric citrate improved multiple aspects of abnormal mineral metabolism and increased hemoglobin in patients with advanced chronic kidney disease (CKD), regardless of their baseline serum phosphate, hemoglobin or iron sufficiency. Furthermore, in the patients randomised to ferric citrate, time to renal replacement therapy (RRT) or death was significantly longer overall and in the subgroup of patients with diabetes.
Danilo Fliser, Homburg/Saar[BA1] , Germany: DKK3 in urine identifies patients with progressive chronic kidney disease
A new biomarker, urinary Dickkopf-related protein-3 (DKK3), identifies chronic kidney disease (CKD) patients at risk of kidney disease progression, regardless of the cause of their kidney injury. The investigators suggest that testing urinary DKK3 might therefore represent a novel diagnostic tool to improve the management of CKD patients and thereby preventing the major burden of illness associated with CKD progression.
 
Highlights

Tomorrow's highlights

Plenary Lecture

10.45-11.30    Congress HALL A1

Bruce Sullenger: From the RNA world to the clinic: RNAs as drugs and drug targets.

 
Image

Are you ready for the debate?

Join an expert panel to discuss “Thrombotic Microangiopathy: navigating the storm” as they take a deeper look at some of the hot topics surrounding TMA assessment, diagnosis and treatment.
Should you be at the 55th ERA-EDTA Congress, don’t miss out: Saturday, May 26, 2018 13:30–14:45, Room C1 M1-2, the Bella Center Copenhagen (congress venue).
Learn more here.
 
Association

'Run for Kidneys 2018’ starts at 4.00 p.m. this afternoon!

Enjoy the 5 km ’Run for Kidneys 2018’ on Friday afternoon! All proceeds will be donated to the MSF (Médecins Sans Frontières). At 3.00 p.m., registration opens and at 4.00 p.m. the race commences!
More info and registration form can be found at the Run venue or at http://www.era-edta2018.org/en-US/run-for-kidneys-2018
 
Image
Visit the ERA-EDTA-Shop and help to help!
Buy nice gifts for your family and friends at the ERA-EDTA Shop and support young nephrologists! All funds collected will be used for travel grants for young nephrologists to attend the 56th ERA-EDTA Congress in Budapest next year.
 
Meet the ERA-EDTA Leaders!
Don't miss the opportunity to meet and network with ERA-EDTA KOLs at the ERA-EDTA Booth (n. 2.291) in the Exhibition Area (Ground floor) on May 25 and May 26, 2018 at 9.30-17.30.
Click here to access the full list.
 
Be Social

Be Social: share your Congress experience!

Use Social Media to share your educational congress experience with colleagues and friends. The official hashtag is #ERAEDTA18. We suggest that you carefully read the Social Media Guidelines.

 
Institutional
ERA-EDTA Council Elections for 2018: Online voting is still possible!
During the General Assembly, three Ordinary Council Members must be elected. Full ERA-EDTA members can vote in this election, which can be done onsite only today until 17.00, and tomorrow immediately before the start of the General Assembly, until 09.30 (CEST), May 26, 2018."
Information about the candidates as well as the link to the online voting can be found here.

Image
Don´t miss the General Assembly tomorrow at 9.30 a.m.
To gain access to the ERA-EDTA General Assembly on May 26 (09.30 to 10.45 in Room C1-M5) you need your membership card.
 
Education
 

For more Learning and Discoveries. Benefit from a range of fully integrated e-educational services

For the 55th Congress, ERA-EDTA is also offering delegates several educational and digital services. Use the Programme Planner to plan your personal agenda and use the mobile app for onsite navigation and to engage in many learning activities. To review sessions you attended or missed, visit ENP at www.enp-era-edta.org to access abstracts, speakers' slides and webcasts, e-posters etc. and to finalise your own slide summaries. Visit the e-campus in Hall E to learn more about rare diseases, view e-posters, get a demo about ENP and much more. We are also offering an ENP Learning Quest onsite. Complete 10 Learning activities and win one of 1000 ENP T-Shirts.
For more info and direct access to the 2018 digital services click here.

 
 
Contact Us
 
Web Site
 
E-Mail
 
Facebook
 
Twitter
 
Google+
 
LinkedIn
 
Instagram
 
YouTube
 
Vimeo
 
 
Image

Initiatives

 
Image

Working Groups

 
Image

Committees...

...and their latest initiatives:

 
Image
Opportunities
 
Image

The advantages of being a member of ERA-EDTA

As a member you will become part of one of the
most influential European Medical Associations!

 

The ERA-EDTA collects and processes personal information to provide you with details regarding the Association and its activities. The information is used for accounting and commercial purposes by ERA-EDTA and/or Euromeetings s.r.l. in compliance with the Italian Legislative Decree 196/2003.